Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service
Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery...
ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics
TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”)...
Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”)...
IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement
To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing...